Login to Your Account


Endocyte soars on news from Europe, phase IIb vintafolide data in NSCLC

By Randy Osborne
Staff Writer

Friday, March 21, 2014
Wall Street hailed Endocyte Inc.’s double play – a positive opinion from European regulators on vintafolide in platinum-resistant ovarian cancer (PROC) and good news from a phase IIb trial in non-small-cell lung cancer (NSCLC) with the same compound – by sending its stock through the roof.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription